Biotechnology company developing therapies for oncology and immunology.
Tourmaline Bio, Inc. is a clinical-stage biotechnology company dedicated to advancing treatments for patients grappling with debilitating immune and inflammatory conditions. At the forefront of its development efforts is TOUR006, a human anti-IL-6 monoclonal antibody designed to specifically target interleukin-6, a pivotal proinflammatory cytokine implicated in the pathogenesis of various autoimmune and inflammatory disorders. The company's robust pipeline extends to innovative medicines and therapies aimed at addressing atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED), underscoring its commitment to pioneering therapeutic solutions.
Established in 2021 and headquartered in New York, New York, Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC before rebranding in September 2022. Leveraging cutting-edge research and development strategies, the company collaborates with leading scientific minds to propel its innovative treatments from concept to clinical reality. By focusing on areas of critical unmet medical need, Tourmaline Bio aims to redefine standards of care and significantly improve the lives of patients worldwide.
Through strategic partnerships and a visionary approach to biopharmaceutical innovation, Tourmaline Bio continues to expand its impact within the healthcare landscape. With a relentless dedication to advancing therapeutic options for immune-mediated diseases, the company strives to achieve transformative outcomes and enhance quality of life for individuals facing challenging medical conditions.